|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19,750.00 KRW | -15.60% |
|
-10.23% | -65.59% |
| 07-23 | Samsung EpiS Unit Signs Cancer Drug Development, Commercialization Deal with IntoCell | MT |
| 12-21 | IntoCell, Inc.(KOSDAQ:A287840) added to S&P Global BMI Index | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| INTOCELL, INC. | Other Biotechnology & Medical Research | -15.60% | -10.23% | -65.59% | -24.33% | - | 203M |  | | |
- Stock Market
- Stocks
- A287840 Stock
- Charts IntoCell, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
